Cite
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.
MLA
Yegya-Raman, Nikhil, et al. “Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.” International Journal of Radiation Oncology, Biology, Physics, vol. 119, no. 1, May 2024, pp. 56–65. EBSCOhost, https://doi.org/10.1016/j.ijrobp.2023.08.047.
APA
Yegya-Raman, N., Berman, A. T., Ciunci, C. A., Friedes, C., Berlin, E., Iocolano, M., Wang, X., Lai, C., Levin, W. P., Cengel, K. A., O’Reilly, S. E., Cohen, R. B., Aggarwal, C., Marmarelis, M. E., Singh, A. P., Sun, L., Bradley, J. D., Plastaras, J. P., Simone II, C. B., & Langer, C. J. (2024). Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 119(1), 56–65. https://doi.org/10.1016/j.ijrobp.2023.08.047
Chicago
Yegya-Raman, Nikhil, Abigail T. Berman, Christine A. Ciunci, Cole Friedes, Eva Berlin, Michelle Iocolano, Xingmei Wang, et al. 2024. “Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.” International Journal of Radiation Oncology, Biology, Physics 119 (1): 56–65. doi:10.1016/j.ijrobp.2023.08.047.